An innovative and stable mRNA-LNP microneedle vaccine elicits humoral and multifunctional cellular immune responses.

Acta Pharm Sin B · 2026 · PMC12827896 · PMID 41584332

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

Seven days after MN immunization, the proportion of CD11c + CD80 + and CD11b + F4/80 + cells in the mLNP and mLNP-man vaccine groups showed an increasing trend, and the mLNP-man group exhibited more significant immune activation characteristics than the mLNP vaccine group ( Fig. 5 A).

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.